Document is current

Article History

Received: 25 November 2023

Accepted: 13 July 2024

First Online: 7 August 2024

Declarations

:

: This study is a retrospective clinical chart review study using routine clinical care data. It is in accordance with the Declaration of Helsinik and was approved by the local ethics committee of Zurich (KEK-ZH 2015-0065). The ethics committee permitted application of the article 34 of the Human Research Act, under which further use of health-related personal data or biological material can be made without informed consent if it would be disproportionately difficult or impossible to obtain consent and provided further conditions are met.

: Not applicable.

: MG has received grant support from the SNF, the Frutiger Foundation and the Emdo Foundation. SW has received in the last 5 years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz and speakers honoraria from Salmon and Takeda. Her work was supported in the last years by the Swiss National Science Foundation (SNF), diff. EU FP7s, Bfarm Germany, ZInEP, Hartmann Müller Stiftung, Olga Mayenfisch, Gertrud Thalmann, Vontobel, Uniscientia, Erika Schwarz Fonds, Heuberg foundation and Horizon Europe. Outside professional activities and interests are declared under the link of the University of Zurich . CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. JA has a position on the board of senior advisors in this International Journal of Bipolar Disorders. The other authors declare no conflict of interest.